1,131
Participants
Start Date
August 31, 2015
Primary Completion Date
May 31, 2019
Study Completion Date
December 5, 2022
TEZ/IVA
Fixed dose tablet for oral administration.
IVA
Tablet for oral administration.
Birmingham
Tucson
Little Rock
Long Beach
Los Angeles
Oakland
Palo Alto
Sacramento
San Diego
Aurora
Denver
Gainesville
Miami
Orlando
Pensacola
Tampa
Atlanta
Boise
Chicago
Glenview
Niles
Peoria
Indianapolis
Iowa City
Lexington
New Orleans
Baltimore
Boston
Ann Arbor
Detroit
Minneapolis
Kansas City
St Louis
Omaha
Lebanon
Long Branch
New Brunswick
Albuquerque
Albany
Buffalo
New Hyde Park
New York
Rochester
Syracuse
Chapel Hill
Akron
Cincinnati
Cleveland
Columbus
Toledo
Oklahoma City
Portland
Philadelphia
Pittsburgh
Charleston
Sioux Falls
Knoxville
Memphis
Nashville
Austin
Dallas
Fort Worth
Houston
Tyler
Salt Lake City
Seattle
Spokane
Morgantown
Milwaukee
Chermside
Melbourne
South Brisbane
Westmead
Graz
Innsbruck
Salzburg
Brussels
Ghent
Leuven
Vancouver
Toronto
Halifax
Montreal
Québec
Copenhagen
Benite Cedex
Bordeaux
Bron
Lille
Marseille
Montpellier
Paris
Rennes
Roscoff
Rouen
Berlin
Bochum
Erlangen
Essen
Frankfurt
Giesen
Hannover
Heidelberg
Jena
München
Tübingen
Würzburg
Cork
Dublin
Limerick
Haifa
Haifa
Jerusalem
Petah Tikva
Tel Litwinsky
Ancona
Genova
Milan
Orbassano
Palermo
Potenza
Roma
Rome
Torino
Verona
Amsterdam
Heidelberglaan
Nijmegen
Rotterdam
The Hague
Barcelona
Madrid
Sabadell
Seville
Valencia
Gothenburg
Stockholm
Uppsala
Bern
Zurich
Leeds
Belfast
Birmingham
Exeter
Glasgow
Leeds
Liverpool
London
Manchester
Newcastle upon Tyne
Penarth
Sheffield
Southampton
Stoke-on-Trent
Vertex Pharmaceuticals Incorporated
INDUSTRY